Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Supernus Pharmaceuticals Inc SUPN
$44.63
▼ -2.15%
($-0.98)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$45.19
Prev Close
$45.61
Day Range
$44.35 – $45.67
52W Range
$32.83 – $59.68
Market Cap
$2.59B
Beta
0.57
EPS (TTM)
$-0.51
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2010-12-28 |
| Shares Out. | 58,040,000 |
| Website | supernus.com ↗ |
| Phone | 13018382500 |
| Employees | 778 |
| Revenue | $207.7M |
| Gross Profit | $184.3M |
| Net Income | -$2.3M |
| Free Cash Flow | $82.2M |
| Total Assets | $1.50B |
| Total Liabilities | $423.9M |
| Equity | $1.08B |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Supernus Pharmaceuticals Inc is a publicly traded company under the ticker symbol SUPN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)